Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Catherine Diefenbach(NYU Langone Health), Fangxin Hong(Dana-Farber Cancer Institute), Richard F. Ambinder(Johns Hopkins University), Jonathon B. Cohen(Emory University), Michael J. Robertson(Indiana University Bloomington), Kevin A. David(Rutgers Cancer Institute of New Jersey), Ranjana H. Advani(Stanford Cancer Institute), Timothy S. Fenske(Medical College of Wisconsin), Stefan K. Barta(University of Pennsylvania), Neil Palmisiano(Thomas Jefferson University), Jakub Svoboda(University of Pennsylvania), David Morgan(Vanderbilt University Medical Center), Reem Karmali(Northwestern University), Elad Sharon(National Cancer Institute), Howard Streicher(National Cancer Institute), Brad S. Kahl(Washington University in St. Louis), Stephen M. Ansell(Mayo Clinic in Arizona)
Cited by 140Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis